Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRV130 QTc and Tolerability Study
NCT02344303Phase 1Completed
- Sponsor
- Trevena, Inc.
- Start
- Dec 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oliceridine in acute pain (2 arms), sponsored by Trevena, Inc. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 4 hours and Change from baseline in QTc at 24 hours. Started Dec 2014; status: completed.
02
Drugs
oliceridine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT02344303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344303.